ASIT biotech

EU: ASIT

€3.8m market cap

€0.18 last close

ASIT biotech is restructuring after the failure of its lead product.

Investment summary

Edison Investment Research is terminating coverage on Abacus Health Products (ABCS), ADL Bionatur (BNT), ASIT Biotech (ASIT), GAME Digital (GMD), International Stem Cell Corporation (ISCO), Powerhouse Energy Group (PHE), Windar Photonics (WPHO). Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.0 (12.0) (12.0) (93.6) N/A N/A
2018A 0.0 (12.8) (14.3) (85.7) N/A N/A
2019E N/A N/A N/A N/A N/A N/A
2020E N/A N/A N/A N/A N/A N/A
Industry outlook

Reported gp-ASIT+ Phase III allergy data showed a statistically proven but inadequate clinical response.

Last updated on 04/09/2020
Register to receive research on ASIT biotech as it is published
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (€m) N/A
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 8.4 (23.3) (85.2)
Relative* 8.7 (20.1) (84.0)
52-week high/low €2.6/€0.2
*% relative to local index
Key management
Michel Baijot CEO
Frank Hazevoets CFO
Yves Desiront CFO